Matches in UGent Biblio for { <https://biblio.ugent.be/publication/5723752#aggregation> ?p ?o. }
Showing items 1 to 48 of
48
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B1011321.
- aggregation creator B1011322.
- aggregation creator B1011323.
- aggregation creator B1011324.
- aggregation creator B1011325.
- aggregation creator B1011326.
- aggregation creator B1011327.
- aggregation creator B1011328.
- aggregation creator B1011329.
- aggregation creator B1011330.
- aggregation creator B1011331.
- aggregation creator B1011332.
- aggregation creator B1011333.
- aggregation creator B1011334.
- aggregation creator B1011335.
- aggregation creator B1011336.
- aggregation creator person.
- aggregation date "2006".
- aggregation format "application/pdf".
- aggregation hasFormat 5723752.bibtex.
- aggregation hasFormat 5723752.csv.
- aggregation hasFormat 5723752.dc.
- aggregation hasFormat 5723752.didl.
- aggregation hasFormat 5723752.doc.
- aggregation hasFormat 5723752.json.
- aggregation hasFormat 5723752.mets.
- aggregation hasFormat 5723752.mods.
- aggregation hasFormat 5723752.rdf.
- aggregation hasFormat 5723752.ris.
- aggregation hasFormat 5723752.txt.
- aggregation hasFormat 5723752.xls.
- aggregation hasFormat 5723752.yaml.
- aggregation isPartOf urn:issn:1527-6465.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12-and 36-month results".
- aggregation abstract "Everolimus is a macrolide immunosuppressive agent with known consistent absorption. In this double-blind study, we examined the safety and tolerability of everolimus vs. placebo in de novo liver transplant recipients. One hundred and nineteen liver allograft recipients were randomized to 1 of 4 groups: everolimus 0.5 mg bid, everolimus 1.0 mg bid, everolimus 2 mg bid, or placebo. Patients received oral cyclosporine to achieve a target trough level of 150-400 ng/mL in combination with prednisone. Primary and secondary endpoints of safety, tolerability, and efficacy were determined at 12 months, and patients were followed through 36 months. There was a trend toward fewer treated acute rejections in the everolimus group than in the placebo group: everolimus 0.5 mg: 39.3%; everolimus 1.0 mg: 30.0%; everolimus 2 mg: 29.0%; placebo: 40.0% (P = not significant). Adverse events were higher in everolimus-treated patients especially at the 4-mg/day dose, but there was no difference in the incidence of thrombocytopenia or leukopenia between all groups and renal function as determined by serum creatinine, and creatinine clearance remained stable to 36 months in everolimus-treated patients. Mean cholesterol and triglycerides increased from baseline in all treatment groups, and maximum levels were seen at 6 months. In conclusion, this study demonstrates that everolimus in combination with oral cyclosporine had an acceptable safety and tolerability profile, paving the way for additional studies in this transplant indication.".
- aggregation authorList BK1418179.
- aggregation endPage "1648".
- aggregation issue "11".
- aggregation startPage "1640".
- aggregation volume "12".
- aggregation aggregates 5732872.
- aggregation isDescribedBy 5723752.
- aggregation similarTo lt.20707.
- aggregation similarTo LU-5723752.